Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2016

Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2016
Published Jun 28, 2016
70 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2016, provides in depth analysis on Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted pipeline therapeutics.

The report provides comprehensive information on the Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
- The report reviews Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
- The report assesses Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

Reasons to buy

  
Source:
Document ID
GMDHC0144TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Overview81
Therapeutics Development93
  Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Stage of Development91
  Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Therapy Area101
  Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Indication111
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Companies142
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Products under Development by Universities/Institutes162
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Therapeutics Assessment186
  Assessment by Monotherapy/Combination Products181
  Assessment by Mechanism of Action191
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Companies Involved in Therapeutics Development247
  Biomics Biotechnologies Co., Ltd.241
  Bioneer Corporation251
  Boehringer Ingelheim GmbH261
  CureVac GmbH271
  MimiVax, LLC281
  Optimum Therapeutics, LLC291
  Polyplus-Transfection SA301
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Drug Profiles3122
  Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer Drug Profile311
  Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology Drug Profile321
  Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors Drug Profile331
  Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer Drug Profile342
  BI-1361849 Drug Profile362
  BKM-1644 Drug Profile381
  BKM-1740 Drug Profile391
  C-10M Drug Profile401
  Cellular Immunotherapy to Target Melan-A, MAGE-3 and Survivin for Melanoma and Uveal Melanoma Drug Profile411
  Cellular Immunotherapy to Target PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer Drug Profile421
  CV-9201 Drug Profile432
  FL-118 Drug Profile452
  MX-106 Drug Profile471
  SurVaxM Drug Profile482
  UC-112 Drug Profile501
  Vaccine for Lymphoma and Colon Carcinoma Drug Profile511
  Vaccine for Oncology Drug Profile521
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Dormant Projects533
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Discontinued Products562
Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) Featured News &Press Releases5811
  May 31, 2016: Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID to Treat Rare Blood Cancer581
  Sep 09, 2015: Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study581
  Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies591
  Apr 21, 2015: SurVaxM Phase I Completed601
  Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer611
  Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent621
  Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent631
  Nov 04, 2013: CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer641
  Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent641
  Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent651
  Nov 07, 2011: CureVac Presents Results Of Phase I/IIa Trial In Non-Small Cell Lung Cancer With CV9201 At 26th Annual SITC Meeting661
  Jun 10, 2011: CureVac Presents Promising New Data For Lung Cancer Vaccine CV9201 At ASCO Conference661
  Jun 16, 2010: CureVac Starts Phase IIa With mRNA Immunotherapeutic In Non-Small Cell Lung Cancer671
  May 26, 2009: CureVac Begins Clinical Study With mRNA Vaccine In Non-Small Cell Lung Cancer672
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Baculoviral-IAP-Repeat-Containing-Protein-5-Apoptosis-Inhibitor-4-or-Apoptosis-Inhibitor-Survivin-or-BIRC5-Pipeline-Review-H1-2016-2088-16046>
  
APA:
Global Markets Direct - Market Research. (2016). Baculoviral IAP Repeat-Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Baculoviral-IAP-Repeat-Containing-Protein-5-Apoptosis-Inhibitor-4-or-Apoptosis-Inhibitor-Survivin-or-BIRC5-Pipeline-Review-H1-2016-2088-16046>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.